Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide and Barrett’s oesophagus (BO) is the most significant risk factor. We evaluated the efficacy of high-dose esomeprazole proton pump inhibitor acid suppression (PPI) and aspirin in improving outcome for...
Main Authors: | Jankowski, J, de Caestecker, J, Love, S, Reilly, G, Watson, P, Sanders, S, Ang, Y, Morris, D, Bhandari, P, Attwood, S, Ragunath, K, Rameh, B, Fullarton, G, Tucker, A, Penman, I, Rodgers, C, Neale, J, Brooks, C, Wise, A, Jones, S, Church, N |
---|---|
Format: | Journal article |
Published: |
Elsevier
2018
|
Similar Items
-
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
by: Jankowski, J, et al.
Published: (2018) -
Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial AspECT Trial
by: Jankowski, JJ, et al.
Published: (2018) -
Barrett's oesophagus patients attending hospital: Baseline clinical, patient history and quality of life data from BOSS and AspECT
by: Love, S, et al.
Published: (2016) -
The changing world of clinical trials 2003-2017: A view from the AspECT trial
by: Reilly, G, et al.
Published: (2017) -
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.
by: Fitzgerald, R, et al.
Published: (2014)